ArticleBJC reports2025
Cancer risk after preeclampsia: a cohort study in two Nordic populations.
Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited evidence suggests that preeclampsia (PE) is associated with reduced cancer risk later in life. We aimed to investigate this using large registry-based cohorts. We hypothesised that enhanced immune activation in PE women, suggested by autoimmune-type reactivity, lowers their subsequent cancer risk.
methodsUtilising Medical Birth Registry data from Sweden and Finland, we identified 123,495 women with PE and 3,223,537 women without. Data were cross-linked to the national Cancer Registries. Incidence rate ratios with 95% CIs were calculated and adjusted for maternal birth year, age at first birth, and parity.
resultsOverall cancer risk was significantly lower in Swedish PE women (IRR 0.91) but not in Finnish. Lower IRRs in PE women were found in both cohorts for breast (IRR 0.90 and 0.91), cervical (IRR 0.79 and 0.55) and lung cancer (IRR 0.72 and 0.63), while endometrial cancer showed increased incidence (IRR 1.28 and 1.46). Foetal sex had no impact on cancer risk. Among Swedish siblings to PE women, a slight reduction in cancer risk, driven by lower lung cancer incidence (IRR 0.86), was noted.
conclusionOur data show a link between PE and subsequent cancer risk, suggesting that shared mechanisms may predispose to PE and influence cancer development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.